1. Academic Validation
  2. Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules

Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules

  • J Med Chem. 2010 Jun 24;53(12):4793-7. doi: 10.1021/jm1000248.
Satyamaheshwar Peddibhotla 1 Ranxin Shi Pasha Khan Layton H Smith Arianna Mangravita-Novo Michael Vicchiarelli Ying Su Karl J Okolotowicz John R Cashman John C Reed Gregory P Roth
Affiliations

Affiliation

  • 1 Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, Florida 32827, USA.
Abstract

A unique series of biologically active chemical probes that selectively inhibit NF-kappaB activation induced by protein kinase C (PKC) pathway activators have been identified through a cell-based phenotypic reporter gene assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further understanding on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis, SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-kappaB activation.

Figures
Products